Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | CTSL | P07711 | 3/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1363856 | 1.00 | GAA (0.34) | GAAKDM4ERAB9ACTSLMAPK10 | |
| SCHEMBL1364611 | 1.00 | GAA (0.34) | GAAKDM4ERAB9ACTSLMAPK10 | |
| SCHEMBL1363886 | 0.91 | POLB (0.39) | GAAKDM4ESMN1; SMN2ALDH1A1MAOA | |
| SCHEMBL1366023 | 0.91 | POLB (0.39) | GAAKDM4ESMN1; SMN2ALDH1A1MAOA | |
| SCHEMBL1364446 | 0.90 | RAB9A (0.34) | GAAKDM4ERAB9ACTSLMAPK10 | |
| SCHEMBL1363809 | 0.90 | RAB9A (0.34) | GAAKDM4ERAB9ACTSLMAPK10 | |
| SCHEMBL12138721 | 0.83 | GAA (0.34) | GAAKDM4ERAB9ASMN1; SMN2NPC1 | |
| SCHEMBL12138708 | 0.83 | GAA (0.34) | GAAKDM4ERAB9ASMN1; SMN2NPC1 | |
| SCHEMBL12306852 | 0.80 | SMN1; SMN2 (0.36) | GAAKDM4ERAB9ACTSLMAPK10 | |
| SCHEMBL1363401 | 0.80 | AR (0.42) | CTSLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224267-A1 | Selective androgen receptor modulators | Radius Health,Inc. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20090253758-A1 | Selective androgen receptor modulators | ELLIPSES PHARMA LTD (GB) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224267-A1 | Selective androgen receptor modulators | AR, SHBG, GPR119 | GAA 4131/4885KDM4E 1482/4885RAB9A 4321/4885 |
| US-20090253758-A1 | Selective androgen receptor modulators | AR, SHBG, GPR119 | GAA 4131/4885KDM4E 1482/4885RAB9A 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.